医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

InnoCare Announces Approval of Clinical Trial of BCL2 Inhibitor ICP-248 in China

2022年09月13日 AM09:30
このエントリーをはてなブックマークに追加


 

BEIJING

InnoCare Pharma (HKEX: 09969) announced today that the Company has received Investigational New Drug (IND) approval of clinical trial from the NMPA (National Medical Products Administration) for its B-cell lymphoma-2 (BCL2) inhibitor ICP-248, which is the Company’s fifth innovative drug to enter the clinical stage in the field of hematology, and also the 13th drug entering the clinic in the pipeline.

ICP-248 is a novel, orally bioavailable BCL2 selective inhibitor, which aims to treat non- Hodgkin’s lymphoma (NHL), acute lymphoblastic leukemia (ALL) and other malignant hematological tumors as a monotherapy or in combination with BTK inhibitors and other drugs. BCL2 is an important part of apoptotic pathway and is overexpressed in a variety of hematologic malignancies. ICP-248 has anti-tumor effects by activating the endogenous mitochondrial apoptosis pathway that causes rapid cancer cell apoptosis.

Dr. Jasmine Cui, the Co-founder, Chairwoman and CEO of InnoCare said, “ICP-248 will further strengthen our hematology pipeline. We have built multiple drugs that cover a variety of important hema-oncology targets such as BTK, CD19, CD20xCD3, BCL2 and E-3 ligase to address the unmet medical needs.”

About InnoCare

InnoCare is a commercial stage biopharmaceutical company committed to discovering, developing, and commercializing first-in-class and/or best-in-class drugs for the treatment of cancer and autoimmune diseases. We strategically focus on liquid cancer, solid tumors, and autoimmune diseases with high unmet medical needs in China and worldwide. InnoCare has branches in Beijing, Nanjing, Shanghai, Guangzhou, Hong Kong and the United States.

InnoCare Forward-looking Statements

This report contains the disclosure of some forward-looking statements. Except for statements of facts, all other statements can be regarded as forward-looking statements, that is, about our or our management’s intentions, plans, beliefs, or expectations that will or may occur in the future. Such statements are assumptions and estimates made by our management based on its experience and knowledge of historical trends, current conditions, expected future development and other related factors. This forward-looking statement does not guarantee future performance, and actual results, development and business decisions may not match the expectations of the forward-looking statement. Our forward-looking statements are also subject to a large number of risks and uncertainties, which may affect our short-term and long-term performance.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220912005570/en/

CONTACT

Media

Chunhua Lu

86-10-66609879

chunhua.lu@innocarepharma.com

Investors


86-10-66609999

ir@innocarepharma.com

同じカテゴリーの記事 

  • Asahi Kasei to Acquire Calliditas Therapeutics AB to Accelerate Growth as a Global Healthcare Company
  • Bio-Sourcing及其合作伙伴利用190万欧元的EUREKA Eurostars补贴启动价值340万欧元的欧盟炎症适应症项目
  • TVM Capital Healthcare宣布聚焦沙特阿拉伯的TVM Healthcare Afiyah Fund结束募资
  • TVMキャピタル・ヘルスケア、 サウジアラビア特化の「TVMヘルスケア・アフィア・ファンド」のクロージングを発表
  • RevolKa Signed Master Service Agreement with Daiichi Sankyo